AstraZeneca’s Tagrisso redefines survival bar in advanced EGFR-mutant NSCLC

AstraZeneca (LSE: AZN; Nasdaq: AZN) has reported final overall survival results from its Phase III FLAURA2 trial, confirming that combining TAGRISSO® (osimertinib) with platinum-based chemotherapy significantly extends life expectancy in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). The data, presented on September 7 at the IASLC 2025 World Conference on Lung Cancer (WCLC) in Barcelona, show a median overall survival (OS) of 47.5 months—nearly four years—compared to 37.6 months for TAGRISSO monotherapy.

The 23% reduction in the risk of death (hazard ratio: 0.77; 95% CI: 0.61–0.96; p=0.0202) not only met the trial’s key secondary endpoint but now positions TAGRISSO plus chemotherapy as the longest-surviving 1st-line regimen ever reported for EGFRm NSCLC patients in a global Phase III trial.

What is the clinical relevance of FLAURA2’s nearly four-year survival benchmark for NSCLC patients?

The final survival analysis of FLAURA2 confirms what oncologists have long anticipated: that first-line use of osimertinib in combination with chemotherapy produces a clinically meaningful survival advantage. Approximately 63.1% of patients on the combination were alive at three years, and 49.1% at four years—compared to 50.9% and 40.8% for the monotherapy group. These gains were observed across all prespecified subgroups, including age, race, mutation type, and CNS metastasis status.

Patients in the monotherapy arm were allowed to receive standard chemotherapy after progression, which strengthens the significance of the OS advantage from the combination. Experts at the WCLC suggested that this survival benefit—reaching nearly four years in a previously high-mortality cohort—could influence international treatment guidelines in the near term.

How does this trial build on the historical use of EGFR-TKIs like TAGRISSO in NSCLC?

Historically, EGFR-tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib significantly improved progression-free survival for patients with EGFRm NSCLC, but resistance and relapse were common. TAGRISSO, a third-generation EGFR-TKI developed to overcome resistance mutations such as T790M, improved upon that foundation in the FLAURA trial by achieving a median OS of 38.6 months.

FLAURA2 advances this legacy. By layering chemotherapy onto TAGRISSO, AstraZeneca is now addressing early resistance mechanisms head-on. The trial enrolled 557 previously untreated patients with Stage IIIB–IV NSCLC across more than 150 sites globally, and compared TAGRISSO plus pemetrexed/platinum chemotherapy to TAGRISSO alone. With OS as the key secondary endpoint and PFS already showing benefit in earlier data cuts, this final survival readout marks a pivotal moment in NSCLC clinical strategy.

What are analysts and institutional investors saying about AstraZeneca’s latest data?

While no specific analyst firms were cited in the announcement, institutional sentiment surrounding AstraZeneca’s oncology pipeline has remained broadly positive. The strong OS result from FLAURA2 adds another durable asset to the company’s lung cancer franchise, which also includes durvalumab (Imfinzi), datopotamab deruxtecan (in collaboration with Daiichi Sankyo), and savolitinib.

Given the competitive environment in NSCLC—where Merck’s KEYTRUDA and Roche’s TECENTRIQ dominate immunotherapy—TAGRISSO’s success as a targeted therapy helps AstraZeneca consolidate its leadership in EGFR-mutated disease. Analysts are likely to view these results as validation of AstraZeneca’s combinatorial approach to targeted therapy and an important differentiator in both clinical and commercial terms.

What are the safety concerns associated with TAGRISSO plus chemotherapy?

The combination therapy’s safety profile was consistent with expectations. Grade 3 or higher adverse events (AEs) occurred in 70% of patients in the combination arm, compared to 34% in the monotherapy group. These higher rates were largely driven by known chemotherapy-related events such as neutropenia, thrombocytopenia, and gastrointestinal toxicities. Still, discontinuation due to AEs remained low: 12% for the combination group and 7% for monotherapy.

Interstitial lung disease (ILD) or pneumonitis occurred in 3.3% of patients in the combination arm (0.4% fatal), and QTc interval prolongation was observed in 1.8% with no arrhythmia-related deaths. Cardiomyopathy was more frequent with the combination (9% vs 3.8% in monotherapy), though fatal events were rare (1.1%).

Ongoing monitoring for cardiotoxicity and pulmonary complications remains critical, particularly in patients with prior risk factors. However, AstraZeneca emphasized that no new safety signals emerged since the initial readout at WCLC 2023, reinforcing the benefit-risk balance of the regimen.

What is the broader regulatory and clinical outlook for TAGRISSO in this setting?

TAGRISSO is already approved as a monotherapy for first-line EGFRm NSCLC in over 120 countries, including the US, EU, China, and Japan. It is also approved in combination with chemotherapy in more than 80 markets. The new FLAURA2 data will likely accelerate updates to treatment guidelines and may encourage earlier adoption of the combination regimen across global oncology practices.

AstraZeneca is not stopping at FLAURA2. The British biopharmaceutical giant is also running multiple late-stage trials testing TAGRISSO in combination with agents like savolitinib (SAFFRON), datopotamab deruxtecan (TROPION-Lung14 and Lung15), and in the post-surgical adjuvant setting (ADAURA2). This broad strategy reflects an ambition to make TAGRISSO the anchor therapy across all disease stages of EGFRm NSCLC—from early-stage to metastatic.

How does this shape AstraZeneca’s leadership position in lung cancer?

AstraZeneca’s lung cancer franchise has become one of its most strategically important therapeutic areas. TAGRISSO alone has been prescribed to more than one million patients worldwide and is now backed by a suite of trials spanning early, locally advanced, and metastatic disease.

The company’s comprehensive pipeline—anchored by both targeted therapies and immuno-oncology combinations—has made it one of the most aggressive players in lung cancer innovation. Its founding role in the Lung Ambition Alliance, a global coalition to improve lung cancer outcomes, reinforces this commitment.

As the landscape shifts toward earlier treatment and combination regimens, AstraZeneca’s ability to deliver durable efficacy while managing toxicity could define its leadership position well into the next decade.